Amelioration of Experimental Autoimmune Uveitis by Leflunomide in Lewis Rats
Authors:
Open Access
- 23 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e62071
Abstract
Purpose To investigate the efficacy of leflunomide in experimental autoimmune uveitis (EAU) in rats. Methods Lewis rats were immunized with interphotoreceptor retinoid-binding peptide (IRBP) in order to generate EAU. Rats received three dose of leflunomide through intragastric administration (prevention or treatment protocols) after immunization at three separate doses (3 mg/kg/d; 6 mg/kg/d; 12 mg/kg/d). Cyclosporin A was administered as a positive) control. Rats were euthanized during peak disease activity (day 14 or 15). Treatment effectiveness was evaluated in vivo using clinical EAU scoring (d14) and histopathological evaluation of enucleated eyes after experimental termination. The expression levels of inflammatory cytokines in the serum were quantified by ELISA. Eyeball of rats were harvested and mRNA expression of interleukin 17 (IL17) and IFN-γ were quantified through RT-PCR. Intracellular expression of interleukin (IL)-17 in the activated CD4(+) T cells was assessed by flow cytometry. The effects of leflunomide inhibition on immune responses in rats were investigated in isolated lymphocytes. Results Histopathological and clinical data revealed severe intraocular inflammation in the immunized rat. Inflammation reached its peak on day 14 in this EAU model. Treatment with leflunomide significantly prevented and treated EAU-induced ocular inflammation and decreased clinical and pathological scores compared to vehicle-treated eyes. Gene expression of IL17 and IFN-γwas markedly reduced in leflunomide-treated eyes. Leflunomide significantly decreased the serum levels of IL17 and IFN-γ. The study of IL17+ T cells in peripheral blood and spleen by flow cytometry showed a decreased number of Th17 cell in rats of leflunomide prevented group. Lymphocytes from animals treated with leflunomide had decreased antigen-specific proliferation in vitro compared with lymphocytes from untreated animals. Conclusions Oral administration of leflunomide effectively suppressed IRBP-induced uveitis in rats. These results suggest that leflunomide may be potentially clinical application in uveitis.Keywords
This publication has 48 references indexed in Scilit:
- Deciphering the role of Th17 cells in human diseaseTrends in Immunology, 2011
- The many faces of Th17 cellsCurrent Opinion in Immunology, 2011
- Current approach in the diagnosis and management of panuveitisIndian Journal Of Ophthalmology, 2010
- Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitisRheumatology, 2009
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector categoryJournal of Experimental Medicine, 2008
- TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1Nature Medicine, 2007
- Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in RatsBritish Journal of Ophthalmology, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Systemic CD4+ T cell phenotype and activation status in intermediate uveitisBritish Journal of Ophthalmology, 2004
- Leflunomide: Inhibition of S-antigen induced autoimmune uveitis in Lewis ratsInflammation Research, 1994